Avalon GloboCare CEO David Jin to unveil exosome commercialization plan at China confab

Avalon GloboCare announced Thursday that CEO David Jin will unveil the launch of the company’s new commercialization plan for its exosome products at a conference in China.

Dr Jin on Saturday will lead a session on “Application of Stem Cell Exosomes” at the Second International Aesthetic Industry Conference in Chengdu.

Exosomes are powerful messengers released by cells into biofluids like plasma/serum, urine, and saliva. Avalon says exosomes can help fight the progression of certain cancers and act as biomarkers to detect tumors.

Source – Proactive Investors

One comment

  1. What is the current status of Exosome therapy in mainland China? What is the logistics importing Exosomes (allograph) into china (ie. customs regulations, fees, etc)? What, if any, licenses are required for sales, distribution, and procedural therapies? Thank you.

Leave a Reply

Your email address will not be published. Required fields are marked *